U.S. FDA Approves Roche/Chugai's Actemra For Second-line RA
This article was originally published in PharmAsia News
Executive Summary
Roche Japanese subsidiary Chugai's novel interleukin-6 inhibitor Actemra gained U.S. FDA approval Jan. 8 for treating patients with moderately to severely active rheumatoid arthritis for whom TNF blockers aren't working - a good beginning but still a ways from the first-line indication the pharma sought and still hopes to gain using data from its risk management programs and other sources
You may also be interested in...
Chugai Sets Record Results In 2009, Lowers Forecasts For 2010
Roche Japanese unit Chugai Pharmaceutical had its best year ever in 2009, posting record revenue and profits thanks largely to Tamiflu (oseltamivir), which saw Japan sales soar nine-fold to ¥76.2 billion ($852.75 million) in response to the Japanese government and local authorities stockpiling flu drugs
Chugai Sets Record Results In 2009, Lowers Forecasts For 2010
Roche Japanese unit Chugai Pharmaceutical had its best year ever in 2009, posting record revenue and profits thanks largely to Tamiflu (oseltamivir), which saw Japan sales soar nine-fold to ¥76.2 billion ($852.75 million) in response to the Japanese government and local authorities stockpiling flu drugs
Japan Approves Eisai's Humira, Mitsubishi Tanabe's Remicade In Same-day Approval For Psoriasis
TOKYO - Tokyo-headquartered Eisai and Osaka-based Mitsubishi Tanabe Pharma Jan. 20 simultaneously received Ministry of Health, Labor and Welfare approval to launch Japan's first fully human biological agents for the additional indication of psoriasis